5 ms·
The issues with Ventavia, if true, are not something typical or expected at all. And it is even less expected that any reported issues will not be followed up b
by NoPie 5y ago
The issues with Ventavia, if true, are not something typical or expected at all. And it is even less expected that any reported issues will not be followed up by the regulator. While it is true that many trials suffer from similar issues, it is not the standard that we should accept.
And I don't understand why so many think that BJM article tries to cast doubt on the entirety of Pfizer's vaccine operation? It is nothing like that at all. It clearly says the issue is with one research organization contracted by Pfizer. Maybe it is because you lack the context and jump to quick conclusions?
- pinneycolton 5y agoThe issue is with how many will interpret that headline. People who already want to believe that 100% of the vaccine research is a sham will run with this. The burden is on BJM to be extremely clear if they don't want to add to the misinformation.
- NoPie 5y agoIt is an issue but that issue has to be solved by different means than having fact-checkers saying that BMJ is wrong. BMJ clearly states at the top of every page that it is meant for healthcare professionals.